| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The specific molecular target of Antidepressant agent 1 is not publicly identified. Based on the CAS number and typical antidepressant research, it may act on serotonin transporters (SERT), norepinephrine transporters (NET), dopamine transporters (DAT), or various serotonin receptors (5-HT1A, 5-HT2A, 5-HT2C), or other targets such as NMDA receptors, tropomyosin receptor kinase B (TrkB), or phosphodiesterases. Without detailed literature, the target remains to be determined. Researchers should consult primary literature for this compound.
|
|---|---|
| ln Vitro |
Antidepressant 1 (Compound I) was created by reducing Compound II with NaBH4-AcOH, yielding a 56% reduction. After compound III is condensed with BrCH2CH(OBu)2, compound II is produced via acid-catalyzed cyclization [1].
In vitro data for Antidepressant agent 1 are not readily available in public sources. For a generic research compound with this designation, typical studies would include evaluation of monoamine reuptake inhibition using radiolabeled neurotransmitter uptake assays in synaptosomes or transfected cells. For example, measure inhibition of [3H]-serotonin, [3H]-norepinephrine, and [3H]-dopamine uptake. Potency (IC₅0) may range from nanomolar to micromolar. The compound might also be tested for binding affinity to various GPCRs, ion channels, and transporters in a safety panel. Cytotoxicity in neuronal cell lines (e.g., SH-SY5Y, PC12) would be assessed at concentrations up to 100 uM. Without specific data, these are general expectations. |
| ln Vivo |
In vivo data for Antidepressant agent 1 are not publicly available. In general, for a compound labeled “Antidepressant agent 1”, preclinical studies would involve rodent models of depression including forced swim test (FST), tail suspension test (TST), chronic mild stress (CMS), and learned helplessness. Typical dosing would be acute (1-30 mg/kg i.p. or p.o.) or chronic (14-28 days). Efficacy would be measured as reduced immobility time in FST/TST or reversal of anhedonia in CMS. The compound may also be evaluated for off-target effects on locomotion (open field test). Without specific literature, these are generic methods.
|
| Enzyme Assay |
For in vitro screening of antidepressant activity, a standard panel includes: (1) Monoamine uptake inhibition: use rat brain synaptosomes or HEK-293 cells expressing human SERT, NET, or DAT. Incubate with test compound (0.1-1000 nM) and [3H]-substrate for 10-15 min, then filter and count. (2) Receptor binding: competitive radioligand binding against a panel of 50+ GPCRs, ion channels, and transporters (e.g., CEREP or Eurofins panels) at 1-10 uM. (3) Monoamine oxidase (MAO) A/B inhibition: measure production of hydrogen peroxide or conversion of kynuramine. (4) Neurogenesis assays: in primary hippocampal neural progenitor cells, measure BrdU incorporation or doublecortin expression after 48-72 h treatment. (5) cAMP or phospho-ERK assays in cells expressing relevant GPCRs.
|
| Cell Assay |
For cellular assays, culture rat pheochromocytoma (PC12) cells or human neuroblastoma SH-SY5Y cells in DMEM with 10% FBS and 1% P/S at 37degC with 5% CO2. For neuroprotection studies, treat cells with corticosterone (100-200 uM) or glutamate (10-100 uM) to induce toxicity, then co-treat with Antidepressant agent 1 (0.1-100 uM) for 24-48 h. Assess cell viability by MTT or LDH release. For neurite outgrowth, differentiate PC12 cells with NGF (50 ng/mL) for 5-7 days in the presence of compound; measure neurite length and number. For cAMP accumulation, treat cells with forskolin (1-10 uM) with/without compound and measure cAMP by ELISA. For calcium imaging, load cells with Fluo-4 AM and measure response to KCl or ATP. For cell proliferation and apoptosis, use EdU incorporation and Annexin V/PI staining.
|
| Animal Protocol |
For in vivo evaluation of antidepressant-like activity, use male C57BL/6J mice (8-10 weeks, 20-25 g) or Sprague-Dawley rats (200-250 g). For forced swim test (FST), pre-treat animals with Antidepressant agent 1 (1, 3, 10, 30 mg/kg i.p. or p.o.) 30-60 min prior to test. Place mouse in a cylinder of water (25degC, depth 15 cm) for 6 min; score immobility during last 4 min. For tail suspension test (TST), suspend mouse by tail for 6 min; record immobility. For chronic mild stress (CMS), subject mice to unpredictable stressors for 4-6 weeks, then treat with compound daily for 2-4 weeks, measure sucrose preference and body weight. For learned helplessness, administer inescapable foot shocks then measure escape latency. For locomotor activity, use open field test to rule out false positives from increased locomotion. For neurochemical analysis, dissect brain regions (prefrontal cortex, hippocampus, striatum) and measure monoamines (5-HT, NE, DA) and metabolites (5-HIAA, DOPAC, HVA) by HPLC-ECD. Collect plasma for PK analysis.
|
| ADME/Pharmacokinetics |
Based on the CAS number, Antidepressant agent 1 has a specific structure but no PK data are publicly available. Typically, such research compounds are soluble in DMSO (≥10 mM). For in vivo studies, formulate in 0.5% methylcellulose, saline, or 10% DMSO/90% PEG300/5% Tween-80. Storage: powder at -20degC, protected from light and moisture. Solutions in DMSO can be stored at -80degC for 6 months. The compound's logP, t1/2, and bioavailability would need to be determined experimentally.
|
| Toxicity/Toxicokinetics |
Safety data for Antidepressant agent 1 are not publicly disclosed. Handle with standard laboratory precautions: use personal protective equipment (gloves, lab coat, safety glasses), avoid inhalation, ingestion, and skin contact. The compound is for research use only and not for human use. No teratogenicity, mutagenicity, or carcinogenicity data are available. Consult any available safety data sheet. Dispose of waste according to local regulations. At typical research doses (≤30 mg/kg in rodents), it may be well-tolerated, but this should be verified.
|
| References |
[1]. V. I. Shvedov, et al. Synthesis and properties of new analogs of pyrazidole-halogeno-derivatives of 1,10-trimethylene-2-ethyl-1,2,3,4-tetrahydropyrazino [1,2-a]indole. Pharmaceutical Chemistry Journal volume 12, pages633-635(1978).
|
| Additional Infomation |
Antidepressant agent 1 (CAS 67411-41-0) is a research compound that has been identified in patent or medicinal chemistry literature as having potential antidepressant activity. However, detailed information on its mechanism, efficacy, and safety is not widely available in the public domain. Researchers should consult original literature (e.g., patent applications, journal articles) to obtain specific data. This compound is not FDA-approved for any indication. It is supplied solely for preclinical research purposes to explore new chemical entities for the treatment of major depressive disorder. Use this product only in controlled laboratory settings.
|
| Molecular Formula |
C16H19BRN2
|
|---|---|
| Molecular Weight |
319.239463090897
|
| Exact Mass |
318.073
|
| CAS # |
67411-41-0
|
| PubChem CID |
2882138
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
3.4
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN1CCN2C3=C(C=C(C=C3)Br)C4=C2C1CCC4
|
| InChi Key |
VRTKXFMWBVSAET-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H19BrN2/c1-2-18-8-9-19-14-7-6-11(17)10-13(14)12-4-3-5-15(18)16(12)19/h6-7,10,15H,2-5,8-9H2,1H3
|
| Chemical Name |
12-bromo-4-ethyl-1,4-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-9(16),10(15),11,13-tetraene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.93 mg/mL (~27.97 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1324 mL | 15.6622 mL | 31.3244 mL | |
| 5 mM | 0.6265 mL | 3.1324 mL | 6.2649 mL | |
| 10 mM | 0.3132 mL | 1.5662 mL | 3.1324 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
